Results 121 to 130 of about 27,184 (256)

Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase

Вопросы вирусологии
Introduction. The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF).
Ekaterina N. Ozhmegova, Anna I. Kuznetsova, Aleksey V. Lebedev, Anastasia A. Antonova, Kristina V. Kim, Yana M. Munchak, Alexander S. Tumanov, Elena V. Kazennova   +7 more
doaj   +1 more source

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate

Scientific Reports
This study aimed to compare the serum lipid profiles between tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) in the long-term treatment of chronic hepatitis B (CHB). We analyzed data from treatment-naïve CHB patients administered with
Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao   +7 more
semanticscholar   +1 more source

Rapid onset of hypercalcemia from high-grade lymphoma in the setting of HIV-related immune reconstitution inflammatory syndrome. [PDF]

, 2019
Hypercalcemia in HIV patients has been previously reported, but 1,25-(OH)2 vitamin D-mediated hypercalcemia, due to increased activity of extrarenal 1-alpha hydroxylase, is rarely described with HIV-related infections or malignancies.
Bikle, Daniel, Kim, Sarah, Kim, Stephanie J, Peluso, Michael J, Shoback, Dolores, Wang, Yongmei   +5 more
core  

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B

Journal of Gastroenterology and Hepatology
Our study evaluated the outcomes of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB).
Heechul Nam, J. Han, S. Lee, Hyun Yang, H. Lee, P. Sung, Myeongjun Song, J. Kwon, J. Jang, U. Chang, C. Kim, Soon Woo Nam, S. Bae, J. Choi, S. Yoon, Jin Mo Yang, Hee Yeon Kim   +16 more
semanticscholar   +1 more source

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

JGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka   +10 more
doaj   +1 more source

Effectiveness, safety, and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV‐1 infection: Final 24‐month results from the prospective German TAFNES cohort study

HIV Medicine
Tenofovir alafenamide (TAF) was introduced in the European Union in 2015 as a novel prodrug of tenofovir showing similar efficacy in clinical trials and a more favorable safety profile than tenofovir disoproxil fumarate (TDF).
Christoph Stephan, C. Spinner, A. Rieke, S. Christensen, S. Mauss, Sandra Schreiber, Boris Albuquerque, Marion Heinzkill, H. Ramroth, H. Stellbrink   +9 more
semanticscholar   +1 more source

Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA

Hepatology Research
Patients with chronic hepatitis B virus (HBV) infection experiencing viral breakthrough (BTH) or partial response (PR) during lamivudine (LAM) or entecavir hydrate (ETV) administration often took ETV plus tenofovir alafenamide fumarate (TAF) due to the ...
Shunsuke Yamada, Yoshihito Uchida, J. Kouyama, Kayoko Naiki, Shohei Tsuji, Hayato Uemura, Kayoko Sugawara, Nobuaki Nakayama, Y. Imai, T. Tomiya, Suguru Mizuno, Satoshi Mochida   +11 more
semanticscholar   +1 more source

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

Open Forum Infectious Diseases
TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)–based regimens.
M. Ait-Khaled, J. Oyee, Adrian Yit Reen Ooi, B. Wynne, Andres Maldonado, B. Jones, Tao Wang   +6 more
semanticscholar   +1 more source

Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection

Pharmaceutics
Pre-exposure prophylaxis (PrEP) with a weekly oral regimen of antiretroviral drugs could be a suitable preventative option for individuals who struggle with daily PrEP or prefer not to use long-acting injectables.
I. Massud, K. Nishiura, S. Ruone, A. Holder, Chuong T. Dinh, Jonathan T Lipscomb, J. Mitchell, George M Khalil, W. Heneine, J. G. Garcίa-Lerma, C. Dobard   +10 more
semanticscholar   +1 more source

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source